Fritextsökning
Artiklar per år
Innehållstyper
-
Karolinska institutet fick 21 nya professorer
Genetiskt orsakade hjärtstopp, kampen på molekylnivå mellan celler och angripande virus och kväveoxidens positiva hälsoeffekter. Det är några av forskningsfälten som Karolinska institutets 21 pinfärska professorer ägnar sig åt.
-
Avtal sluts mellan stora svenska och nederländska aktörer
Fyra överenskommelser mellan svenska och nederländska life science-aktörer ska skrivas idag. Avtalen signeras i samband med det pågående statsbesöket från Nederländerna under en ceremoni där ministrar från de bägge länderna medverkar.
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta
-
Business Swedens nya garde – De rullar ut den blågula mattan
Mixen av mycket medicinskt kunnande och en tech-sektor som växer sig allt starkare är en framgångsfaktor för Sverige, enligt Business Swedens life science-team. – Det är en perfekt storm, en bra perfekt storm, säger Britta Stenson, Program Manager.
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”
For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.
-
Nytt nummer av Life Science Sweden – Intervjuer, reportage och nyheter
I det nya numret kan du bland annat läsa en längre intervju med en av de mest framgångsrika entreprenörerna genom tiderna i svensk life science.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Han leder Sectras nya satsning inom genomik
Medicinteknikbolaget Sectra startar en ny affärsenhet för innovation och utveckling inom området genomik, studiet av arvsmassan. Meningen är att företagets plattform för diagnostik i framtiden ska utökas till att hantera även information om individers arvsanlag.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
Trippelgodkännande för Astra Zeneca i Japan
Tre olika läkemedel från Astra Zeneca har godkänts i Japan. De rör sig om behandlingar mot lungcancer i tidigt stadium, bröstcancer samt muskelsjukdomen myastenia gravis.
-
Diagnostikbolag från Umeå kan bli Årets exportsuccé
Umeåföretaget Nordic Biomarker, som utvecklar koagulationsdiagnostik, har gått till final i Årets exportsuccé.
-
Life science-branschen i enad front mot antibiotikaresistens
Flertalet organisationer inom life science bildar Svensk industriallians mot antibiotikaresistens för att tillsammans bromsa utvecklingen.
-
Bifall i USA för uppdaterade covid-19-vacciner mot omikron
Federala hälsomyndigheter i USA har gett sitt bifall till modifierade påfyllnadsdoser av covid-19 vaccin mot omkironvarianten som ska kunna rullas ut i höst. Det skriver Dow Jones Newswires.
-
Här visar Astra Zeneca framtidens läkemedelsfabrik
Automatisering är ledordet i framtidens läkemedelsfabrik. I veckan visade Astra Zeneca hur den kan se ut när man slog upp dörren till företagets "Smart Factory Hub" i Södertälje.
-
Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”
“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportunities,” Björn Arvidsson writes in a column.
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave for drug development in a broader context", writes Marie Gårdmark in a column.
-
Nanexa flyttar in i nya lokaler – ska få bolaget att växa
Igår invigdes Nanexas nya pilotanläggning i Uppsala. Det 300 kvadratmeter stora renrummet gör anläggningen unik, menar bolagets vd David Westberg.
-
Ny CBO hos Bioinvent
Cancerforskningsföretaget Bioinvent har rekryterat Sylvie Ryckebusch till rollen som Chief Business Officer.
BREAKING